Ciprofloxacin [CPFX, chemical name 1-cyclopropyl-6-
fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-
carboxylic acid)] exhibits notable antimicrobial activity,
excellent pharmacokinetic properties, and fewer side
effects, used widely in clinical practice for the treatment
of various bacterial infections [4–6]. Moreover, CPFX
has been recommended as the second-line anti-TB agents
by the World Health Organization for the treatment of
TB mainly in cases involving resistance or intolerance to
first-line anti-TB therapy [7]. Various CPFX derivatives
have been synthesized in order to improve the anti-TB
activity, and some of them possess excellent in vitro and
in vivo activity against both drug-sensitive and MDR
MTB strains [8–10].